XmAb7195

BIOLOGICAL2 trials

Sponsors

Xencor, Inc.

Conditions

Allergic ConjunctivitisAllergic RhinitisAtopic DermatitisAtopic DiseaseHealthy Volunteers

Phase 1

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

CompletedNCT02148744

Xencor, Inc.Allergic Conjunctivitis, Allergic Rhinitis, Atopic Dermatitis

Start: 2014-05-31End: 2015-09-21Updated: 2017-01-24

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

CompletedNCT02881853

Xencor, Inc.Atopic Disease, Healthy Volunteers

Start: 2016-08-17End: 2017-02-24Updated: 2017-07-11